Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 14/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.53 |
| ▸ | HPN | P05981 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinobucol SCHEMBL347492 | 0.92 | VCAM1 (1.00) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL8353439 | 0.91 | VCAM1 (0.90) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL8352308 | 0.90 | VCAM1 (0.82) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL8353431 | 0.90 | VCAM1 (0.82) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL6054982 | 0.90 | VCAM1 (0.92) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL12042604 | 0.89 | VCAM1 (0.81) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL8100563 | 0.87 | VCAM1 (0.90) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL12042606 | 0.86 | VCAM1 (0.81) | VCAM1ALOX15HPNMAPTSIRT5 | |
| SCHEMBL8191857 | 0.86 | VCAM1 (0.79) | VCAM1ALOX15HPNMAPTSIRT5 | |
| Elsibucol SCHEMBL6002307 | 0.85 | VCAM1 (0.73) | VCAM1ALOX15HPNMAPTSIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622604-B2 | via grignard intermediate such as benzylmagnesium chloride and esterification with succinic anhydride; inflammatory and cardiovascular diseases; optimizes the amount of monoester in the final product mixture and minimizes the amount of reagents; e.g. synthesis of succinobucol | SALUTRIA PHARMACEUTICALS LLC (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622604-B2 | via grignard intermediate such as benzylmagnesium chloride and esterification with succinic anhydride; inflammatory and cardiovascular diseases; optimizes the amount of monoester in the final product mixture and minimizes the amount of reagents; e.g. synthesis of succinobucol | SALUTRIA PHARMACEUTICALS LLC (US) | 2009-11-24 | — | — | US | disclosed |
| US-20080009642-A1 | Process of Preparing Esters and Ethers of Probucol and Derivatives Thereof | CRABTREE ACQUISITION CO, LLC | 2008-01-10 | — | — | US | disclosed |
| US-20080009642-A1 | Process of Preparing Esters and Ethers of Probucol and Derivatives Thereof | CRABTREE ACQUISITION CO, LLC | 2008-01-10 | — | — | US | disclosed |
| US-7294737-B2 | Process of preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| US-7294737-B2 | Process of preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| US-20070260087-A1 | Process of Preparing Esters and Ethers of Probucol and Derivatives Thereof | ATHEROGENICS, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070260087-A1 | Process of Preparing Esters and Ethers of Probucol and Derivatives Thereof | ATHEROGENICS, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-7273948-B2 | Process of preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS, INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-7273948-B2 | Process of preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS, INC. (US) | 2007-09-25 | — | — | US | disclosed |
| WO-2007044726-A2 | METHODS FOR REDUCING PLATELET ACTIVATION AND FOR THE TREATMENT OF THROMBOTIC EVENTS | ATHEROGENICS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| WO-2005102323-A2 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | ATHEROGENICS, INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| WO-2003039231-A2 | COMPOUNDS AND METHODS FOR TREATING TRANSPLANT REJECTION | ATHEROGENICS, INC. (US) | 2003-05-15 | — | — | WO | disclosed |
| WO-2002087556-A9 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | ATHEROGENICS INC (US) | 2003-03-20 | — | — | WO | disclosed |
| EP-0637959-B1 | SOLUBLE ANALOGS OF PROBUCOL | ATHEROGENICS INC (US) | 2002-08-21 | — | — | EP | disclosed |
| EP-1161946-A2 | Soluble analogs of probucol | AtheroGenics, Inc. (US) | 2001-12-12 | — | — | EP | disclosed |
| EP-0637959-A4 | SOLUBLE ANALOGS OF PROBUCOL. | UNIV CALIFORNIA (US) | 1995-03-29 | — | — | EP | disclosed |
| EP-0637959-A1 | SOLUBLE ANALOGS OF PROBUCOL | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-02-15 | — | — | EP | disclosed |
| US-5262439-A | Including succinobucol (AGI-1067), monosuccinic acid ester of probucol; oxidation related conditions | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1993-11-16 | — | — | US | disclosed |
| WO-1993021914-A1 | SOLUBLE ANALOGS OF PROBUCOL | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1993-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009642-A1 | Process of Preparing Esters and Ethers of Probucol and Derivatives Thereof | NR3C2, MGLL, GCG | VCAM1 4649/4885ALOX15 1829/4885HPN 2326/4885 |
| US-20070260087-A1 | Process of Preparing Esters and Ethers of Probucol and Derivatives Thereof | CETP, PNLIP, CEL | VCAM1 2904/4885ALOX15 417/4885HPN 1608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.